Exelixis, Inc. $EXEL Stock Position Increased by Capital Impact Advisors LLC

Capital Impact Advisors LLC lifted its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 441.0% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 1,094,466 shares of the biotechnology company’s stock after acquiring an additional 892,161 shares during the quarter. Exelixis accounts for about 3.8% of Capital Impact Advisors LLC’s investment portfolio, making the stock its 7th largest holding. Capital Impact Advisors LLC’s holdings in Exelixis were worth $47,970,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. Caligan Partners LP lifted its stake in shares of Exelixis by 1.8% during the 4th quarter. Caligan Partners LP now owns 1,553,262 shares of the biotechnology company’s stock valued at $68,079,000 after buying an additional 27,532 shares in the last quarter. AQR Capital Management LLC lifted its stake in shares of Exelixis by 48.8% during the 4th quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company’s stock valued at $598,647,000 after buying an additional 4,477,029 shares in the last quarter. Lazard Asset Management LLC lifted its stake in shares of Exelixis by 8.8% during the 4th quarter. Lazard Asset Management LLC now owns 323,499 shares of the biotechnology company’s stock valued at $14,179,000 after buying an additional 26,064 shares in the last quarter. Equitable Holdings Inc. lifted its stake in shares of Exelixis by 18.8% during the 4th quarter. Equitable Holdings Inc. now owns 14,540 shares of the biotechnology company’s stock valued at $637,000 after buying an additional 2,305 shares in the last quarter. Finally, Laird Norton Wetherby Trust Company LLC purchased a new stake in shares of Exelixis during the 4th quarter valued at approximately $398,000. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on EXEL. Zacks Research cut shares of Exelixis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, March 5th. Truist Financial upgraded shares of Exelixis to a “strong-buy” rating in a research note on Monday, April 27th. Stifel Nicolaus increased their target price on shares of Exelixis from $44.00 to $47.00 and gave the stock a “hold” rating in a research note on Wednesday, May 6th. HC Wainwright increased their target price on shares of Exelixis from $54.00 to $56.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Finally, TD Cowen increased their target price on shares of Exelixis from $51.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $47.35.

Exelixis Price Performance

NASDAQ EXEL opened at $52.44 on Thursday. Exelixis, Inc. has a 1 year low of $33.76 and a 1 year high of $53.93. The stock has a market capitalization of $13.18 billion, a PE ratio of 17.42, a P/E/G ratio of 1.50 and a beta of 0.41. The company’s 50 day simple moving average is $48.50 and its two-hundred day simple moving average is $45.09.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.12. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The business had revenue of $610.81 million for the quarter, compared to analysts’ expectations of $607.51 million. During the same period in the prior year, the company posted $0.55 EPS. The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. On average, research analysts anticipate that Exelixis, Inc. will post 3.16 EPS for the current year.

Insider Activity

In other news, EVP Dana Aftab sold 43,451 shares of Exelixis stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $50.35, for a total transaction of $2,187,757.85. Following the completion of the sale, the executive vice president directly owned 594,741 shares of the company’s stock, valued at approximately $29,945,209.35. The trade was a 6.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Christopher J. Senner sold 34,901 shares of the company’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $50.00, for a total transaction of $1,745,050.00. Following the completion of the transaction, the chief financial officer owned 952,317 shares of the company’s stock, valued at $47,615,850. This trade represents a 3.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 219,170 shares of company stock worth $10,620,641. Corporate insiders own 2.60% of the company’s stock.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.